Advertisement
Advertisement
U.S. markets close in 4 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Bright Minds Biosciences Inc. (DRUG)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8620+0.0120 (+0.42%)
As of 10:39AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close2.8500
Open2.9400
Bid2.8600 x 1000
Ask2.9000 x 900
Day's Range2.8600 - 2.9400
52 Week Range2.7500 - 8.9500
Volume3,795
Avg. Volume212,775
Market Cap34.591M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.7680
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DRUG

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bright Minds Biosciences Inc.
    Daily – Vickers Top Insider Picks for 01/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    5 days agoArgus Research
View more
  • GlobeNewswire

    Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference

    VANCOUVER, British Columbia, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, and Alan Kozikowski, PhD, Chief Scientific Officer, will present virtually at the H.C. Wainwright Bioconnect Conference as follows: Date: January 1

  • Newsfile

    Canadian Securities Exchange's November 2021 Performance Includes Strong Listings Growth and New Financing Milestone

    Toronto, Ontario--(Newsfile Corp. - December 15, 2021) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of November 2021, which was highlighted by near-record listings growth and a new financing milestone.November 2021 Operating StatisticsTrading volume of CSE-listed securities totaled 2.6 billion shares;Trading value of CSE-listed securities was $2.1 billion;CSE issuers completed 82 financings that raised an aggregate $250 million;

  • GlobeNewswire

    Bright Minds Biosciences to Present at the Stifel GMP 2nd Annual Future of Healthcare Conference

    VANCOUVER, British Columbia, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference as follows: Date: Wednesday, December 8, 2021 Time: 3:00PM ET W

Advertisement
Advertisement